Raphaël Rousseau

Raphaël Rousseau, M.D., Ph.D. joined Day One as Chief Medical Officer in May 2023. Raphaël is a renowned leader in the biotech industry with more than 25 years of experience building clinical development teams and leading phase 1 to 4 adult and pediatric clinical trials in academia, large and small biopharmaceutical companies. Prior to Day One, Raphaël was Chief Medical Officer at Neogene Therapeutics and Gritstone, where he launched several global Phase 1-2 clinical trials in personalized neoantigen-targeting engineered T cells and cancer vaccines. Prior to those positions, he created and led the innovative pediatric drug development group at Roche and Genentech, overseeing their pediatric strategy across the company’s oncology portfolio. He led the pediatric development and registration of several small molecule inhibitors and immune checkpoint blockers in close collaboration with European and North American academic pediatric oncology consortiums. Raphaël is a graduate of Texas Children’s Cancer Center pediatric hematology-oncology fellowship and Center for Cell and Gene Therapy at Baylor College of Medicine. He obtained his M.D. and graduated from Paris University pediatric residency program where he also received his Ph.D. in therapeutic biotechnologies.